The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Maximizing the Therapeutic Potential of HSP90 Inhibitors
Open accessAbstract
HSP90 is required for maintaining the stability and activity of a diverse group of client proteins, including protein kinases, transcription factors, and steroid hormone receptors involved in cell signaling, proliferation, survival, oncogenesis, and cancer progression. Inhibition of HSP90 alters the HSP90-client protein complex, leading to reduced activity, misfolding, ubiquitination, and, ultimately, proteasomal degradation of client proteins. HSP90 inhibitors have demonstrated significant antitumor activity in a wide variety of preclinical models, with evidence of selectivity for cancer versus normal cells. In the clinic, however, the efficacy of this class of therapeutic agents has been relatively limited to date, with promising responses mainly observed in breast and lung cancer, but no major activity seen in other tumor types. In addition, adverse events and some significant toxicities have been documented. Key to improving these clinical outcomes is a better understanding of the cellular consequences of inhibiting HSP90 that may underlie treatment response or resistance. This review considers the recent progress that has been made in the study of HSP90 and its inhibitors and highlights new opportunities to maximize their therapeutic potential. Mol Cancer Res; 13(11); 1445–51. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · cited 1×
“Although combinatorial approaches are attractive, clinical failures of some combinations in recent years highlight the need to proceed only based on the soundest biologic rationale coupled with robust Pharmacological Audit Trail biomarker studies and an awareness of potential for increased side effects (77, 78).”
BackgroundSelf-citationRoe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex
Ali, M. M. U., Roe, S. M., Vaughan, C. K., Meyer, P., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2006) · Nature · doi:10.1038/nature04716 · Cited by 962 · cited 2×
“All forms of Hsp90 naturally exist as obligate homodimers comprising two identical monomers, each with three distinct functional domains (9, 10).”
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Self-citationThe Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy
Scherz-Shouval, R., Santagata, S., Mendillo, M. L., Sholl, L. M., Ben-Aharon, I., Beck, A. H., Dias-Santagata, D., Koeva, M., Stemmer, S. M., Whitesell, L., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.045 · Cited by 386
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307
Self-citation
Cited by
Chalcone Derivatives: Role in Anticancer Therapy
Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021) · Biomolecules · doi:10.3390/biom11060894 · Cited by 399
Hsp90 and Hsp70 chaperones: Collaborators in protein remodeling
Genest, O., Wickner, S., & Doyle, S. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev118.002806 · Cited by 382
Athanasiou, D., Aguila, M., Bellingham, J., Li, W., McCulley, C., Reeves, P. J., & Cheetham, M. E. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.002 · Cited by 373
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370
Salehi, B., Quispe, C., Chamkhi, I., El Omari, N., Balahbib, A., Sharifi-Rad, J., Bouyahya, A., Akram, M., Iqbal, M., Docea, A. O., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592654 · Cited by 351
Metadata
- Authors
- Butler, L. M., Ferraldeschi, R., Armstrong, H. K., Centenera, M. M., & Workman, P.
- Venue
- Molecular Cancer Research
- Published
- 2015-11-12
- Volume
- 13
- Issue
- 11
- Pages
- 1445-1451
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2162343852
- Cited by
- 208
- References
- 8
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maximizing the Therapeutic Potential of HSP90 Inhibitors. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-15-0234
- The paper
- Butler, L. M., Ferraldeschi, R., Armstrong, H. K., Centenera, M. M., & Workman, P. (2015). Maximizing the Therapeutic Potential of HSP90 Inhibitors. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-15-0234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.